AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. (AURORA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02102165|
Recruitment Status : Suspended (suspended temporarily - amending protocol)
First Posted : April 2, 2014
Last Update Posted : January 18, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer.
In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Breast Cancer||Procedure: metastatic lesion biopsy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.|
|Actual Study Start Date :||April 2014|
|Actual Primary Completion Date :||March 2021|
|Estimated Study Completion Date :||March 2031|
Experimental: metastatic lesion biopsy
biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
Procedure: metastatic lesion biopsy
a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
- Metastatic Breast Cancer (MBC) understanding [ Time Frame: 1 year after end of acrrual ]To improve the understanding of MBC by performing high coverage Targeted Gene Sequencing (TGS) and RNA sequencing on matched primary and metastatic samples to explore tumor heterogeneity, clonal evolution and transcriptional changes associated with mutational and copy number variation (CNV) patterns.
- Building new therapeutic hypotheses [ Time Frame: 1 year after end of accrual and subsequently during follow up period of 10 years ]To build new therapeutic hypotheses based on findings generated by Targeted Gene Sequencing (TGS).
- Patients' prognosis determination [ Time Frame: 1 year after end of accrual and subsequently during follow up period of 10 years ]To evaluate the prognostic relevance of genomic alterations detected in tumor metastatic biopsies and archived primary tissue
- Identification of "exceptional responders" and "rapid progressors"; the outlier patients [ Time Frame: 1 year after end of accrual and subsequently during follow up period of 10 years ]To discover biomarkers of response and/or resistance to systemic therapy using genomic and transcriptomics data of "exceptional responders" and "rapid progressors" (collectively referred to as "outliers", as defined in the AURORA protocol)
- Feasibility of implementing a global molecular screening platform for MBC [ Time Frame: 1 year after end of accrual ]To provide evidence that can contribute in assessing the feasibility of implementing a global molecular screening platform of MBC
- Correlation between molecular alterations and standardly assessed efficacy endpoints [ Time Frame: 1 year after end of accrual and subsequently during follow up period of 10 years ]To correlate molecular alterations in patients with the efficacy endpoints (response rate, progression-free survival and overall survival) set forth in clinical study protocols.
- Patient identification to match with biomarker-driven clinical trials [ Time Frame: on ongoing basis during 3 years' patient recruitment ]To identify patients with candidate driver alterations in their tumors that can be matched to biomarker-driven clinical trials.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Women or men with metastatic or locally relapsed breast cancer manageable with systemic therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
- Written informed consent prior to enrollment into the program.
- Patient aged ≥ 18 years
- Patient agrees to provide archived primary tumor tissue
- Patient agrees to provide newly collected metastatic lesions tissue samples (archived material up to 6 months is allowed provided both Formalin Fixed Paraffin Embedded (FFPE) block and Frozen Tissue are available and were collected from the same lesion at the same time)
- Patient agrees to provide blood samples
- The patient has received more than 1 line of systemic therapy (any type) in the metastatic setting
- Patients who have received prior palliative radiotherapy to the only site that is accessible to biopsy
- Patients with bone-only metastatic disease
- Patients with brain-only metastatic disease, unless surgical excision is planned (in which case tissue will be collected for AURORA purpose)
- Known presence of severe hematopoietic, renal, and/or hepatic dysfunction (according to the local PI)
- Platelet count<100 000/mm3, INR>1.5 (international normalized ratio; blood clotting time) , Albumin<30
- Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin
- Any anti-VEGF (vascular endothelial growth factor) or anti-VEGFR (vascular endothelial growth factor receptor) treatment administered less than 4 weeks before new biopsy procedure or no appropriate wash-out period for patients on anticoagulation therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02102165
|Principal Investigator:||Philippe Aftimos, MD||Institut Jules Bordet, Brussels, Belgium|
|Principal Investigator:||Mafalda Oliveira, MD||University Hospital Vall d'Hebron,Barcelona, Catalonia, Spain|
|Responsible Party:||Breast International Group|
|Other Study ID Numbers:||
1408-BCG ( Other Identifier: EORTC )
GBG 85 ( Other Identifier: German Breast Cancer Group (GBG) )
ICR-CTSU/2014/10050 ( Other Identifier: The Institute of Cancer Research, UK )
|First Posted:||April 2, 2014 Key Record Dates|
|Last Update Posted:||January 18, 2023|
|Last Verified:||January 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
targeted gene sequencing
Neoplasms by Site